Flotek is a small oilfield technology company with two business lines: specialty chemistry for well completions and real-time data analytics for the oil and gas industry. The Chemistry Technologies (CT) segment is Flotek's larger business by revenue, where Flotek designs, manufactures, and sells specialty chemical formulations — primarily for hydraulic fracturing and completion operations. Its flagship CT service, Prescriptive Chemistry Management (PCM), involves analyzing reservoir data and prescribing customized chemistry blends to maximize hydrocarbon recovery. A significant portion of CT revenue comes from a long-term supply agreement with ProFrac Services, which includes minimum purchase commitments and shortfall fees. The Data Analytics (DA) segment is Flotek's growth business, deploying proprietary optical near-infrared spectrometers to measure hydrocarbon quality and composition in real time. DA has three core applications: PWRtek (monitoring and conditioning field gas to fuel turbines and engines, displacing diesel), Digital Valuation (real-time custody transfer monitoring using its XSPCT spectrometer, which became the first optical spectrometer certified to the GPA 2172 custody transfer standard), and Flare Monitoring (tracking gas flare composition for EPA compliance). DA generates revenue through recurring equipment rental and service contracts at high gross margins, as well as outright equipment sales. Flotek's strategy is to evolve from a chemistry company into a data-driven technology company, expanding PWRtek deployments, scaling XSPCT custody transfer installations, and growing its international chemistry business — particularly in the Middle East and Argentina.
Read full business overview →Mid to long-term bullish thesis
View →Mid to long-term bearish thesis
View →Mid to long-term bull-bear debate
View → NEWSummary and scoring of the bull-bear debate
View →Find ideas with similar bull or bear theses
View →Investor-relevant company attributes
View →Key risks to the business
View →Comparisons of annual risk disclosures
View →